BUZZ-Precision BioSciences 股价涨 因 FDA 加速审批肌肉萎缩症疗法

路透中文
Mar 09
BUZZ-Precision BioSciences 股价涨 因 FDA 加速审批肌肉萎缩症疗法

3月9日 - ** 药物开发商 Precision BioSciences DTIL.O 股价盘前上涨 10%,至 5.09 美元

** 该公司称,FDA授予其实验性杜兴氏症疗法PBGENE-DMD "快速通道 "资格

** 该公司称,DMD是一种罕见的遗传性疾病,会导致进行性肌肉衰弱和丧失,主要发生在男孩身上;PBGENE-DMD旨在修复导致这种疾病的常见遗传错误

** 公司表示计划在 2-7 岁的男孩中开展中期试验,以测试安全性和有效性

** 美国食品和药物管理局的 "快速通道 "标签旨在加快开发和审查治疗未满足医疗需求的严重疾病的药物

** 2025 年股价上涨约 9%

(为便利非英文母语者,路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误,或未能包含所需语境,路透不保证自动化翻译文本的准确性,仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失,路透不承担任何责任。)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10